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BACKGROUND: Remote ischemic preconditioning (RIPC) has emerged as an
attractive strategy in clinical settings. Despite convincing evidence of the critical
role played by circulating humoral mediators, their actual identities remain
unknown. In this study, we aimed to identify RIPC-induced humoral mediators using
a proteomic approach.
METHODS: and Results Rats were exposed to 10-min limb ischemia followed by 5-
(RIPC 5') or 10-min (RIPC 10') reperfusion prior to blood sampling. The control
group only underwent blood sampling. Plasma samples were analyzed using
surface-enhanced laser desorption and ionization - time of flight - mass
spectrometry (SELDI-TOF-MS). Three protein peaks were selected for their
significant increase in RIPC 10'. They were identified and confirmed as
apolipoprotein A-I (ApoA-I). Additional rats were exposed to myocardial ischemia-
reperfusion (I/R) and assigned to one of the following groups RIPC+myocardial
infarction (MI) (10-min limb ischemia followed by 10-min reperfusion initiated 20
minutes prior to myocardial I/R), ApoA-I+MI (10 mg/kg ApoA-I injection 10 minutes
before myocardial I/R), and MI (no further intervention). In comparison with
untreated MI rats, RIPC reduced infarct size (52.2±3.7% in RIPC+MI vs.
64.9±2.6% in MI; p<0.05). Similarly, ApoA-I injection decreased infarct size
(50.9±3.8%; p<0.05 vs. MI).
CONCLUSIONS: RIPC was associated with a plasmatic increase in ApoA-I.
Furthermore, ApoA-I injection before myocardial I/R recapitulated the
cardioprotection offered by RIPC in rats. This data suggests that ApoA-I may be a
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